Continuous Glucose Monitoring in Primary Care
A paradigm shift in diabetes management — and how community physicians can use it well
About this event
Continuous glucose monitoring has moved from a niche tool for type 1 diabetes to a mainstream technology that is reshaping how we manage every form of dysglycemia. This 90-minute educational session covers the evidence base for CGM across both type 1 and type 2 diabetes, how to read CGM reports including Ambulatory Glucose Profile (AGP) and time-in-range metrics, patient selection considerations, and practical implementation in a community practice setting. This talk is non-promotional and not product-specific. The focus is on the device category and the evidence base, not on any one manufacturer's sensor.
Learning objectives
- Review current evidence for CGM in type 1 and type 2 diabetes
- Identify which patients are most likely to benefit from CGM
- Interpret AGP reports, time-in-range, GMI, and glycemic variability
- Discuss insurance coverage, prescribing logistics, and patient education
- Evaluate when to integrate CGM data with HbA1c-based monitoring
What to expect
Dinner served from 6:30 PM. Talk runs 7:00–8:30 PM with Q&A to follow. Free parking on site. A printed AGP-interpretation reference card will be provided to each attendee. Please RSVP by Monday June 22 — limited seating.
Speaker
Dr. Peter Ling, MD, FRCPC
University Health Network · Toronto General Hospital
Endocrinologist at Toronto General Hospital with a clinical focus on diabetes care and emerging technologies in glycemic management. Frequent speaker on continuous glucose monitoring, time-in-range outcomes, and bridging endocrine practice with community primary care.
Sponsor
Pharmaceutical
Sponsor disclosure
This program is supported by an educational grant from Abbott Canada. The sponsor had no role in content selection, speaker selection, or scientific conclusions. Speaker financial disclosures will be presented at the start of the session. This activity is accredited by CFPC.